313 related articles for article (PubMed ID: 18405971)
1. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
Wells RA; Leber B; Buckstein R; Lipton JH; Hasegawa W; Grewal K; Yee K; Olney HJ; Larratt L; Vickars L; Tinmouth A
Leuk Res; 2008 Sep; 32(9):1338-53. PubMed ID: 18405971
[TBL] [Abstract][Full Text] [Related]
2. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
[TBL] [Abstract][Full Text] [Related]
3. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
4. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
Mittelman M; Lugassy G; Merkel D; Tamary H; Sarid N; Rachmilewitz E; Hershko C; ;
Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
[No Abstract] [Full Text] [Related]
5. Iron overload in MDS-pathophysiology, diagnosis, and complications.
Gattermann N; Rachmilewitz EA
Ann Hematol; 2011 Jan; 90(1):1-10. PubMed ID: 20938663
[TBL] [Abstract][Full Text] [Related]
6. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
7. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
[TBL] [Abstract][Full Text] [Related]
8. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
Malcovati L
Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
[TBL] [Abstract][Full Text] [Related]
9. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
10. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
Imran F; Phatak P
Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome.
Cuijpers ML; Raymakers RA; Mackenzie MA; de Witte TJ; Swinkels DW
Br J Haematol; 2010 May; 149(3):322-33. PubMed ID: 20067561
[TBL] [Abstract][Full Text] [Related]
12. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
Dreyfus F
Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
[TBL] [Abstract][Full Text] [Related]
13. [The role of iron metabolism in myelodysplastic syndromes].
Finelli C; Clissa C; Stanzani M
Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
[TBL] [Abstract][Full Text] [Related]
14. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
[TBL] [Abstract][Full Text] [Related]
15. Iron chelation therapy in MDS: does it improve survival?
Leitch HA
Leuk Res; 2010 Jul; 34(7):852-3. PubMed ID: 20346508
[No Abstract] [Full Text] [Related]
16. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
[TBL] [Abstract][Full Text] [Related]
17. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Int J Hematol; 2008 Jul; 88(1):24-29. PubMed ID: 18581200
[TBL] [Abstract][Full Text] [Related]
18. Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.
Leitch HA; Buckstein R; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Shamy A; Elemary M; Wells RA
Leuk Res; 2018 Nov; 74():21-41. PubMed ID: 30286330
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.
Ko BS; Chang CS; Chang MC; Chen TY; Chiou TJ; Chiu CF; Huang WL; Kao WY; Lan YJ; Lin SF; Tan TD; Tang JL; Tzeng CH; Wang PN; Yet SP; Tien HF
Int J Hematol; 2014 Jul; 100(1):7-15. PubMed ID: 24924953
[TBL] [Abstract][Full Text] [Related]
20. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
Tefferi A; Stone RM
Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273
[No Abstract] [Full Text] [Related]
[Next] [New Search]